Lv1
38 积分 2021-02-02 加入
Development of a Manufacturing Process for a Key (S)-5-(2,2-Dimethyltetrahydro-2H-pyran-4-yl)-1H-indole Intermediate for Orforglipron. Part II. Development of a CSTR Process for Evans Auxiliary-Assisted Asymmetric 1,4-Addition
1天前
已完结
Process Development of the BACE Inhibitors BI 1147560 BS and BI 1181181 MZ
1天前
已完结
Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting C797S Mutation
2天前
已完结
One-step synthesis of site-specific antibody–drug conjugates by reprograming IgG glycoengineering with LacNAc-based substrates
10天前
已完结
Abstract PR015: Discovery of LY4050784 (FHD-909), a selective BRM (SMARCA2) ATPase inhibitor for the treatment of BRG1(SMARCA4) mutant cancers
10天前
已完结
RNA therapeutics history and future perspectives
18天前
已关闭
Drug delivery systems for RNA therapeutics
18天前
已完结
RNA chemistry and therapeutics
20天前
已完结
A pseudo-label supervised graph fusion attention network for drug–target interaction prediction
21天前
已完结
Safety assessment of antibody-drug conjugates: Nonclinical toxicology, non-active ingredients, and environmental risk considerations
22天前
已关闭
皖公网安备34019202002308
